OTHER INFORMATION
−Removed: During the quarter ended June
+Added: During the quarter ended September
30, 2025, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as
2 unchanged sentences
incorporated by reference into, this Quarterly Report on Form 10-Q.
+Added: Description of Exhibit
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
16 unchanged sentences
ESTRELLA IMMUNOPHARMA, INC.
+Added: /s/ Cheng Liu
Chief Executive Officer
3 unchanged sentences
Principal Executive Officer and Chairman
−Removed: August 11, 2025
+Added: November 12, 2025
(Principal Executive Officer)
Principal Financial Officer
−Removed: August 11, 2025
+Added: November 12, 2025
(Principal Financial Officer and Principal Accounting Officer)
1 unchanged sentence
Chairperson and Director
−Removed: August 11, 2025
+Added: November 12, 2025
/s/ Marsha Roberts
−Removed: August 11, 2025
+Added: November 12, 2025
Marsha Roberts
−Removed: August 11, 2025
+Added: November 12, 2025
/s/ Janelle Wu
−Removed: August 11, 2025
−Removed: August 11, 2025
+Added: November 12, 2025
+Added: November 12, 2025
+Added: /s/ Dengyao Jia
+Added: November 12, 2025
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.